Home
VYNE
VYNE News

Latest VYNE Therapeutics Inc. (VYNE) News on May 9, 2025

VYNE Therapeutics Reports 2025 First Quarter Financial Results and Provides Business Update

GlobeNewswire

a day ago

VYNE Therapeutics Reports 2025 First Quarter Financial Results and Provides Business Update

VYNE Therapeutics Provides Update on VYN202 Program

GlobeNewswire

14 days ago

VYNE Therapeutics Provides Update on VYN202 Program

VYNE Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

GlobeNewswire

2 months ago

VYNE Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

VYNE Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St.

2 months ago

VYNE Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

VYNE Therapeutics Reports 2024 Fourth Quarter and Year-End Financial Results and Provides Business Update

GlobeNewswire

2 months ago

VYNE Therapeutics Reports 2024 Fourth Quarter and Year-End Financial Results and Provides Business Update

VYNE Therapeutics to Participate in March Investor Conferences

GlobeNewswire

3 months ago

VYNE Therapeutics to Participate in March Investor Conferences

VYNE Therapeutics Initiates Phase 1b Trial of VYN202, a Novel BD2-Selective Oral BET Inhibitor, in Plaque Psoriasis

GlobeNewswire

3 months ago

VYNE Therapeutics Initiates Phase 1b Trial of VYN202, a Novel BD2-Selective Oral BET Inhibitor, in Plaque Psoriasis

3 US Penny Stocks To Watch With Market Caps Over $20M

Simply Wall St.

3 months ago

3 US Penny Stocks To Watch With Market Caps Over $20M

Argus Research

4 months ago

Daily – Vickers Top Buyers & Sellers for 01/17/2025

VYNE Therapeutics Completes Enrollment in Phase 2b Trial Evaluating VYN201 for the Treatment of Nonsegmental Vitiligo

GlobeNewswire

4 months ago

VYNE Therapeutics Completes Enrollment in Phase 2b Trial Evaluating VYN201 for the Treatment of Nonsegmental Vitiligo

US Penny Stocks To Watch In December 2024

Simply Wall St.

4 months ago

US Penny Stocks To Watch In December 2024

H.C. Wainwright says VYNE’s VYN202 becomes ‘pick of the crop’ after MAD data

TipRanks

5 months ago

H.C. Wainwright says VYNE’s VYN202 becomes ‘pick of the crop’ after MAD data

VYNE Therapeutics Reports Positive Top-line Phase 1a MAD Data for VYN202, its Novel BD2-Selective BET Inhibitor

GlobeNewswire

5 months ago

VYNE Therapeutics Reports Positive Top-line Phase 1a MAD Data for VYN202, its Novel BD2-Selective BET Inhibitor

VYNE Therapeutics initiated with a Buy at BTIG on I&I potential

TipRanks

6 months ago

VYNE Therapeutics initiated with a Buy at BTIG on I&I potential

VYNE Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St.

6 months ago

VYNE Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

VYNE Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire

6 months ago

VYNE Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

We Think VYNE Therapeutics (NASDAQ:VYNE) Needs To Drive Business Growth Carefully

Simply Wall St.

7 months ago

We Think VYNE Therapeutics (NASDAQ:VYNE) Needs To Drive Business Growth Carefully

VYNE Therapeutics Announces Positive Phase 1a SAD Data for VYN202, a Novel BD2-Selective BET Inhibitor

GlobeNewswire

8 months ago

VYNE Therapeutics Announces Positive Phase 1a SAD Data for VYN202, a Novel BD2-Selective BET Inhibitor

VYNE Therapeutics to Participate in September Investor Conferences

GlobeNewswire

8 months ago

VYNE Therapeutics to Participate in September Investor Conferences

VYNE Therapeutics Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St.

9 months ago

VYNE Therapeutics Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

VYNE Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire

9 months ago

VYNE Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

VYNE Therapeutics Announces Granting of Composition of Matter Patent for VYN202, a Novel BD2-Selective BET Inhibitor

GlobeNewswire

10 months ago

VYNE Therapeutics Announces Granting of Composition of Matter Patent for VYN202, a Novel BD2-Selective BET Inhibitor

One VYNE Therapeutics Insider Raised Stake By 55% In Previous Year

Simply Wall St.

10 months ago

One VYNE Therapeutics Insider Raised Stake By 55% In Previous Year

VYNE Therapeutics Announces Appointment of Subhashis Banerjee, M.D. as Senior Vice President of Clinical Development

GlobeNewswire

10 months ago

VYNE Therapeutics Announces Appointment of Subhashis Banerjee, M.D. as Senior Vice President of Clinical Development

VYNE Therapeutics to Participate in Leerink Partners Therapeutics Forum

GlobeNewswire

10 months ago

VYNE Therapeutics to Participate in Leerink Partners Therapeutics Forum

VYNE Therapeutics Announces Dosing of First Participants in Phase 1a Trial of Novel BD2-Selective BET Inhibitor VYN202

GlobeNewswire

a year ago

VYNE Therapeutics Announces Dosing of First Participants in Phase 1a Trial of Novel BD2-Selective BET Inhibitor VYN202

Lotto 6/49 - $64 million up for grabs in the next draw!

CNW Group

a year ago

Lotto 6/49 - $64 million up for grabs in the next draw!

Returns On Capital At B&S Group (AMS:BSGR) Paint A Concerning Picture

Simply Wall St.

a year ago

Returns On Capital At B&S Group (AMS:BSGR) Paint A Concerning Picture

Seoul says it will resume loudspeaker propaganda against North

AFP

a year ago

Seoul says it will resume loudspeaker propaganda against North

It Might Not Be A Great Idea To Buy PATRIZIA SE (ETR:PAT) For Its Next Dividend

Simply Wall St.

a year ago

It Might Not Be A Great Idea To Buy PATRIZIA SE (ETR:PAT) For Its Next Dividend

OUTsurance Group Insiders Placed Bullish Bets Worth R25.5m

Simply Wall St.

a year ago

OUTsurance Group Insiders Placed Bullish Bets Worth R25.5m

Fed Meeting, Inflation Report, Apple’s WWDC, Broadcom Earnings, and More to Watch This Week

Barrons.com

a year ago

Fed Meeting, Inflation Report, Apple’s WWDC, Broadcom Earnings, and More to Watch This Week

Just Three Days Till BREMER LAGERHAUS-GESELLSCHAFT -Aktiengesellschaft von 1877- (FRA:BLH) Will Be Trading Ex-Dividend

Simply Wall St.

a year ago

Just Three Days Till BREMER LAGERHAUS-GESELLSCHAFT -Aktiengesellschaft von 1877- (FRA:BLH) Will Be Trading Ex-Dividend

An Intrinsic Calculation For ORIOR AG (VTX:ORON) Suggests It's 35% Undervalued

Simply Wall St.

a year ago

An Intrinsic Calculation For ORIOR AG (VTX:ORON) Suggests It's 35% Undervalued

VYNE Therapeutics Announces Dosing of First Subject in Phase 2b Vitiligo Trial of Novel BET Inhibitor VYN201

GlobeNewswire

a year ago

VYNE Therapeutics Announces Dosing of First Subject in Phase 2b Vitiligo Trial of Novel BET Inhibitor VYN201

VYNE Reports First Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire

a year ago

VYNE Reports First Quarter 2024 Financial Results and Provides Business Update

VYNE Therapeutics Announces FDA Clearance of IND Application for VYN202, a Novel BD2-Selective BET Inhibitor

GlobeNewswire

a year ago

VYNE Therapeutics Announces FDA Clearance of IND Application for VYN202, a Novel BD2-Selective BET Inhibitor

VYNE Therapeutics Announces Oral Presentations for VYN201 at the 2024 Society for Investigative Dermatology (SID) Annual Meeting

GlobeNewswire

a year ago

VYNE Therapeutics Announces Oral Presentations for VYN201 at the 2024 Society for Investigative Dermatology (SID) Annual Meeting

VYNE Therapeutics (NASDAQ:VYNE) Is In A Good Position To Deliver On Growth Plans

Simply Wall St.

a year ago

VYNE Therapeutics (NASDAQ:VYNE) Is In A Good Position To Deliver On Growth Plans

VYNE Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference

GlobeNewswire

a year ago

VYNE Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference

VYNE Therapeutics Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St.

a year ago

VYNE Therapeutics Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag

VYNE Reports 2023 Fourth Quarter and Year-End Financial Results and Provides Business Update

GlobeNewswire

a year ago

VYNE Reports 2023 Fourth Quarter and Year-End Financial Results and Provides Business Update

VYNE Therapeutics to Present Results of the Phase 1b Trial for VYN201 at the 2024 Global Vitiligo Foundation Annual Scientific Symposium

GlobeNewswire

a year ago

VYNE Therapeutics to Present Results of the Phase 1b Trial for VYN201 at the 2024 Global Vitiligo Foundation Annual Scientific Symposium

VYNE Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference

GlobeNewswire

a year ago

VYNE Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference

Favourable Signals For VYNE Therapeutics: Numerous Insiders Acquired Stock

Simply Wall St.

a year ago

Favourable Signals For VYNE Therapeutics: Numerous Insiders Acquired Stock

Ace Global Business Acquisition Limited Announces Additional Contribution to Trust Account to Extend Period to Consummate Business Combination

PR Newswire

a year ago

Ace Global Business Acquisition Limited Announces Additional Contribution to Trust Account to Extend Period to Consummate Business Combination

Elicio Therapeutics Announces Publication of Preclinical Data Demonstrating TCR-T Cell Therapy in Combination with Lymph Node-Targeted Amphiphile-Immunotherapy Enhanced Anti-Tumor Function and Eradicated Solid Tumors

GlobeNewswire

a year ago

Elicio Therapeutics Announces Publication of Preclinical Data Demonstrating TCR-T Cell Therapy in Combination with Lymph Node-Targeted Amphiphile-Immunotherapy Enhanced Anti-Tumor Function and Eradicated Solid Tumors

Taysha Gene Therapies Announces Poster Presentation on TSHA-102 in Rett Syndrome at Upcoming British Paediatric Neurology Association 2024 Annual Conference

GlobeNewswire

a year ago

Taysha Gene Therapies Announces Poster Presentation on TSHA-102 in Rett Syndrome at Upcoming British Paediatric Neurology Association 2024 Annual Conference

SteveWillDoIt Does Safety Shot: One of the Top Influencers on Social Media Partners with Safety Shot, a Wellness Beverage that Reduces Blood Alcohol & Boosts Clarity

GlobeNewswire

a year ago

SteveWillDoIt Does Safety Shot: One of the Top Influencers on Social Media Partners with Safety Shot, a Wellness Beverage that Reduces Blood Alcohol & Boosts Clarity

Elicio Therapeutics to Present ELI-002 7P (AMPLIFY-7P) Trial in Progress Poster on Phase 1/2 Study of Lymph Node-Targeted Vaccine at ASCO GI Symposium

GlobeNewswire

a year ago

Elicio Therapeutics to Present ELI-002 7P (AMPLIFY-7P) Trial in Progress Poster on Phase 1/2 Study of Lymph Node-Targeted Vaccine at ASCO GI Symposium

Sidoti Events, LLC's Virtual January Micro-Cap Conference

ACCESSWIRE

a year ago

Sidoti Events, LLC's Virtual January Micro-Cap Conference

Elicio Therapeutics to Present at the B. Riley Securities 4th Annual Oncology Conference

GlobeNewswire

a year ago

Elicio Therapeutics to Present at the B. Riley Securities 4th Annual Oncology Conference

VYNE Therapeutics Announces Positive Biomarker Data from Successful Phase 1b Trial of VYN201 for the Treatment of Vitiligo

GlobeNewswire

a year ago

VYNE Therapeutics Announces Positive Biomarker Data from Successful Phase 1b Trial of VYN201 for the Treatment of Vitiligo

Newswire Unveils its Media Suite, an All-in-One Solution for Media Engagement

ACCESSWIRE

a year ago

Newswire Unveils its Media Suite, an All-in-One Solution for Media Engagement

VYNE Therapeutics Appoints Christine Borowski, Ph.D., to its Board of Directors

GlobeNewswire

a year ago

VYNE Therapeutics Appoints Christine Borowski, Ph.D., to its Board of Directors

Newswire Named Leader in Press Release Distribution in G2's Winter 2024 Report

ACCESSWIRE

a year ago

Newswire Named Leader in Press Release Distribution in G2's Winter 2024 Report

Palatin Receives Notice of Acceptance of the Listing Standards Compliance Plan from NYSE American

PR Newswire

a year ago

Palatin Receives Notice of Acceptance of the Listing Standards Compliance Plan from NYSE American

ACCESSWIRE Scores Top Honors in G2’s Winter 2024 Report Including, Best Usability

ACCESSWIRE

a year ago

ACCESSWIRE Scores Top Honors in G2’s Winter 2024 Report Including, Best Usability

Are Medical Stocks Lagging Bausch Health (BHC) This Year?

Zacks

a year ago

Are Medical Stocks Lagging Bausch Health (BHC) This Year?

HeartBeam Unveils AI Program Designed to Deliver Unprecedented Personalized Cardiac Insights

Business Wire

a year ago

HeartBeam Unveils AI Program Designed to Deliver Unprecedented Personalized Cardiac Insights

U.S. Forest Service Issues an Environmental Assessment and Draft Decision of No Significant Impact on Solitario's Proposed Golden Crest Drilling Program

ACCESSWIRE

a year ago

U.S. Forest Service Issues an Environmental Assessment and Draft Decision of No Significant Impact on Solitario's Proposed Golden Crest Drilling Program

Shareholders in Crown Crafts (NASDAQ:CRWS) are in the red if they invested three years ago

Simply Wall St.

a year ago

Shareholders in Crown Crafts (NASDAQ:CRWS) are in the red if they invested three years ago

Insider Spends US$59k Buying More Shares In Crown Crafts

Simply Wall St.

a year ago

Insider Spends US$59k Buying More Shares In Crown Crafts

Crown Crafts (NASDAQ:CRWS) Is Due To Pay A Dividend Of $0.08

Simply Wall St.

a year ago

Crown Crafts (NASDAQ:CRWS) Is Due To Pay A Dividend Of $0.08

Palatin Technologies, Inc. (AMEX:PTN) Q1 2024 Earnings Call Transcript

Insider Monkey

a year ago

Palatin Technologies, Inc. (AMEX:PTN) Q1 2024 Earnings Call Transcript

Thomson Reuters StreetEvents

a year ago

Q1 2024 Palatin Technologies Inc Earnings Call

Pioneer's Third Quarter Revenue Increases 99.1% to a Record $12.4 Million; Grows Profitability to $0.10 in Quarterly EPS

PR Newswire

a year ago

Pioneer's Third Quarter Revenue Increases 99.1% to a Record $12.4 Million; Grows Profitability to $0.10 in Quarterly EPS

VYNE Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire

a year ago

VYNE Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

Bright Health Group, Inc. (NYSE:BHG) Q3 2023 Earnings Call Transcript

Insider Monkey

2 years ago

Bright Health Group, Inc. (NYSE:BHG) Q3 2023 Earnings Call Transcript

VYNE Therapeutics to Host Virtual R&D Day Event on November 9, 2023

GlobeNewswire

2 years ago

VYNE Therapeutics to Host Virtual R&D Day Event on November 9, 2023

VYNE Therapeutics Announces Closing of Previously Announced Private Placement of $88.2 Million

GlobeNewswire

2 years ago

VYNE Therapeutics Announces Closing of Previously Announced Private Placement of $88.2 Million

Share on Social Networks: